Post-Translational Modifications and Diabetes
Diabetes and its associated complications have increasingly become major challenges for global healthcare. The current therapeutic strategies involve insulin replacement therapy for type 1 diabetes (T1D) and small-molecule drugs for type 2 diabetes (T2D). Despite these advances, the complex nature o...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-03-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/14/3/310 |
| _version_ | 1827306894476181504 |
|---|---|
| author | Chiranjeev Sharma Abu Hamza Emily Boyle Dickson Donu Yana Cen |
| author_facet | Chiranjeev Sharma Abu Hamza Emily Boyle Dickson Donu Yana Cen |
| author_sort | Chiranjeev Sharma |
| collection | DOAJ |
| description | Diabetes and its associated complications have increasingly become major challenges for global healthcare. The current therapeutic strategies involve insulin replacement therapy for type 1 diabetes (T1D) and small-molecule drugs for type 2 diabetes (T2D). Despite these advances, the complex nature of diabetes necessitates innovative clinical interventions for effective treatment and complication prevention. Accumulative evidence suggests that protein post-translational modifications (PTMs), including glycosylation, phosphorylation, acetylation, and SUMOylation, play important roles in diabetes and its pathological consequences. Therefore, the investigation of these PTMs not only sheds important light on the mechanistic regulation of diabetes but also opens new avenues for targeted therapies. Here, we offer a comprehensive overview of the role of several PTMs in diabetes, focusing on the most recent advances in understanding their functions and regulatory mechanisms. Additionally, we summarize the pharmacological interventions targeting PTMs that have advanced into clinical trials for the treatment of diabetes. Current challenges and future perspectives are also provided. |
| first_indexed | 2024-04-24T18:30:08Z |
| format | Article |
| id | doaj.art-72dc85f879804ea59a7b7b1139e2f30c |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-04-24T18:30:08Z |
| publishDate | 2024-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-72dc85f879804ea59a7b7b1139e2f30c2024-03-27T13:27:55ZengMDPI AGBiomolecules2218-273X2024-03-0114331010.3390/biom14030310Post-Translational Modifications and DiabetesChiranjeev Sharma0Abu Hamza1Emily Boyle2Dickson Donu3Yana Cen4Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23219, USADepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23219, USADepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23219, USADepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23219, USADepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23219, USADiabetes and its associated complications have increasingly become major challenges for global healthcare. The current therapeutic strategies involve insulin replacement therapy for type 1 diabetes (T1D) and small-molecule drugs for type 2 diabetes (T2D). Despite these advances, the complex nature of diabetes necessitates innovative clinical interventions for effective treatment and complication prevention. Accumulative evidence suggests that protein post-translational modifications (PTMs), including glycosylation, phosphorylation, acetylation, and SUMOylation, play important roles in diabetes and its pathological consequences. Therefore, the investigation of these PTMs not only sheds important light on the mechanistic regulation of diabetes but also opens new avenues for targeted therapies. Here, we offer a comprehensive overview of the role of several PTMs in diabetes, focusing on the most recent advances in understanding their functions and regulatory mechanisms. Additionally, we summarize the pharmacological interventions targeting PTMs that have advanced into clinical trials for the treatment of diabetes. Current challenges and future perspectives are also provided.https://www.mdpi.com/2218-273X/14/3/310post-translational modificationsdiabetesT1DT2Dclinical trials |
| spellingShingle | Chiranjeev Sharma Abu Hamza Emily Boyle Dickson Donu Yana Cen Post-Translational Modifications and Diabetes Biomolecules post-translational modifications diabetes T1D T2D clinical trials |
| title | Post-Translational Modifications and Diabetes |
| title_full | Post-Translational Modifications and Diabetes |
| title_fullStr | Post-Translational Modifications and Diabetes |
| title_full_unstemmed | Post-Translational Modifications and Diabetes |
| title_short | Post-Translational Modifications and Diabetes |
| title_sort | post translational modifications and diabetes |
| topic | post-translational modifications diabetes T1D T2D clinical trials |
| url | https://www.mdpi.com/2218-273X/14/3/310 |
| work_keys_str_mv | AT chiranjeevsharma posttranslationalmodificationsanddiabetes AT abuhamza posttranslationalmodificationsanddiabetes AT emilyboyle posttranslationalmodificationsanddiabetes AT dicksondonu posttranslationalmodificationsanddiabetes AT yanacen posttranslationalmodificationsanddiabetes |